Diane Armstrong, MD
Family Medicine · Fairfield, OHNPI 1104913508
Payments from drug & device makers
Across 67 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$193
- Imperative Care, Inc$176
- Amgen$135
- Abbott$105
- Astellas Pharma US Inc$57
- Lilly USA, LLC$57
- plus $390 from 18 others
What the payments were for
- Food & beverage$1,113100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $193 |
| Imperative Care, Inc | 6 | $176 |
| Amgen(2 entities) | 10 | $135 |
| Abbott | 5 | $105 |
| Astellas Pharma US Inc | 4 | $57 |
| Lilly USA, LLC | 4 | $57 |
| Amarin Pharma, Inc. | 3 | $45 |
| Novartis | 3 | $41 |
| UCB, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Boehringer Ingelheim | 2 | $29 |
| Johnson & Johnson | 2 | $25 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Pfizer | 2 | $22 |
| GSK | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Sobi, Inc | 1 | $17 |
| Heartflow, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Novo Nordisk | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
| Tactile Systems Technology Inc | 1 | $12 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
How this compares
$1,113 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 119 | $128,683 |
| EliquisApixaban | 88 | $94,439 |
| OzempicSemaglutide | 77 | $92,012 |
| JardianceEmpagliflozin | 67 | $91,925 |
| XareltoRivaroxaban | 73 | $77,598 |
| TrulicityDulaglutide | 24 | $43,259 |
| RybelsusSemaglutide | 36 | $39,706 |
| JanuviaSitagliptin Phosphate | 52 | $39,357 |
| FarxigaDapagliflozin Propanediol | 36 | $30,741 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $27,619 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $22,931 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 22 | $18,487 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $15,665 |
| MovantikNaloxegol Oxalate | 14 | $8,889 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $7,919 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $57 | $171,942143 claims |
| Novo NordiskOzempic, Rybelsus | $13 | $131,718113 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $29 | $98,17080 claims |
| PfizerEliquis | $22 | $94,43988 claims |
| Johnson & JohnsonXarelto | $25 | $77,59873 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $20 | $35,15157 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $25 | $5,30825 claims |
| Astellas Pharma US IncMyrbetriq | $57 | $3,67619 claims |
| AbbVieSavella | $193 | $3,22313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Fairfield
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.